Intra-VTA Orexin Receptor Antagonist Injection
Objective: To assess the effects of selective orexin receptor antagonist SB334867A injected directly into the ventral tegmental area (VTA) on morphine-induced place preference in rats
This is a Intra-VTA Orexin Receptor Antagonist Injection protocol using rat as the model organism. The procedure involves 4 procedural steps, 2 equipment items, 2 materials. Extracted from a 2006 paper published in Journal of Neuroscience.
Model and subjects
rat • Not specified • unknown • Not specified • Not specified
Study window
Estimated timing pending
Core workflow
Prepare orexin receptor antagonist solution • Perform intra-VTA microinjection • Administer morphine
Primary readouts
- Morphine-induced place preference (suppression by SB334867A)
- Hyperlocomotion behavior
Key equipment and reagents
Use this page as an execution guide, then fall back to the source paper whenever you need exact exclusions, dosing details, or assay-specific caveats.
Confirm first
- Verify the animal model, intervention setup, and collection timepoints against the source paper.
- Check that every direct vendor link matches the exact specification your lab plans to run.
Use the page like this
- Work through the protocol steps in order and use the inline vendor chips only when you need to source or verify an item.
- Jump to Experimental Context for readouts, data shape, and analysis flow before planning downstream analysis.
Protocol Steps
Start here. The step list is optimized for running the experiment, with direct vendor links available inline when you need to source a cited item.
Prepare orexin receptor antagonist solution
Prepare SB334867A solution for microinjection into the VTA
Note: SB334867A is a selective orexin receptor antagonist with chemical structure 1-(2-methylbenzoxazol-6-yl)-3-[1.5]naphthyridin-4-yl urea
View evidence from paper
“An intra-VTA injection of a selective orexin receptor antagonist SB334867A [1-(2-methylbenzoxazol-6-yl)-3-[1.5]naphthyridin-4-yl urea]”
Perform intra-VTA microinjection
Inject SB334867A directly into the ventral tegmental area of rats using microinjection technique
Note: Injection targets the ventral tegmental area where orexin receptors are coexpressed with tyrosine hydroxylase
View evidence from paper
“An intra-VTA injection of a selective orexin receptor antagonist SB334867A significantly suppressed the morphine-induced place preference in rats”
Administer morphine
Administer morphine subcutaneously to induce place preference and hyperlocomotion
Note: Morphine is a µ-opioid receptor agonist
View evidence from paper
“The subcutaneous morphine-induced place preference and hyperlocomotion observed in wild-type mice”
Measure place preference behavior
Assess morphine-induced place preference in the behavioral apparatus following SB334867A injection and morphine administration
Note: Place preference is measured as a behavioral outcome of the morphine-orexin system interaction
View evidence from paper
“An intra-VTA injection of a selective orexin receptor antagonist SB334867A significantly suppressed the morphine-induced place preference in rats”